Compare Biogen Inc (BIIB) vs iShares S&P GSCI Commodity-Indexed Trust ETF (GSG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs iShares S&P GSCI Commodity-Indexed Trust ETF — how do they compare? Biogen Inc trades at $193.46 (market cap $28.34B), while iShares S&P GSCI Commodity-Indexed Trust ETF trades at $30.98. Which is the better fit depends on your goals.
| BIIB | GSG | |
|---|---|---|
Market Cap | $28.34B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $216.63 | $34.77 |
52-Week Low | $122.68 | $22.06 |
Enterprise Value | $30.62B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
GSG trades at $30.52, up 3.6% with a bullish technical signal. Moving averages and oscillators support upward momentum, though the 6-day RSI indicates overbought conditions. Recent news highlights institutional shifts toward commodities, aligning with GSG's focus. Key support lies near $30, with resistance at $31.
The outlook remains positive amid commodity-driven market themes, but overbought technicals and reliance on macroeconomic trends pose risks. Upside depends on sustained commodity demand and institutional inflows, while volatility may test near-term support levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About iShares S&P GSCI Commodity-Indexed Trust ETF
GSG is a diversified commodity ETF that tracks the S&P GSCI Total Return Index. It provides exposure to a broad basket of futures, including energy, metals, and agriculture, with a significant weighting toward the energy sector.
Read more on GSG →
